Guggenheim analyst Subbu Nambi initiated coverage of NeoGenomics (NEO) with a Neutral rating.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target lowered to $12 from $18 at Piper Sandler
- NeoGenomics, Sherwin-Williams, Grab, Paccar, First Solar: Trending by Analysts
- NeoGenomics: Hold Rating Amid Mixed Performance and Uncertain MRD Pathway
- NeoGenomics price target lowered to $10 from $17 at Morgan Stanley
- NeoGenomics price target lowered to $12 from $17 at TD Cowen
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue